Prothrombin G20210A Mutation, Blood
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Direct mutation analysis for the prothrombin (PT) G20210A allele should be reserved for patients with clinically suspected thrombophilia. There may be additional indications for direct PT G20210A mutation testing, such as in determining the duration of anticoagulation therapy of venous thromboembolism patients and screening for women contemplating hormone therapy.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Direct Mutation Analysis
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Prothrombin 20210 mutation